Cover Image
Market Research Report
Product code 
1091860

Asia-pacific Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2030

Published: | Inkwood Research | 175 Pages | Delivery time: 2-3 business days

Price

Back to Top
Asia-pacific Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2030
Published: June 21, 2022
Inkwood Research
Content info: 175 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

KEY FINDINGS

The Asia-Pacific Alzheimer's disease therapeutics & diagnostics market is set to progress with a 6.89% CAGR across the forecasting period of 2022 to 2030. The rising prevalence of dementia and rapidly growing population in developing countries are driving the market growth.

MARKET INSIGHTS

The Asia-Pacific Alzheimer's disease therapeutics & diagnostics market growth estimation covers the analysis of South Korea, Thailand, Indonesia, China, India, Vietnam, Australia & New Zealand, Japan, and Rest of Asia-Pacific. The Indian healthcare system is experiencing immense progress due to the growing economy. The demand for new healthcare technological advancements in the treatment and early diagnosis of dementia and cognitive impairment is rising due to the increasing burden of Alzheimer's disease throughout the country.

Furthermore, the entire population of South Korea is rapidly aging. According to the World Population Ageing 2019 report, the population aged above 65 years or above is expected to reach 12.658 million by 2030, which was 7.715 million in 2019. The surging geriatric population is prone to neurological disorders like Alzheimer's disease and other dementias, which is expected to drive the market over the forecast period.

Additionally, according to Alzheimer's Disease International, in 2015, Alzheimer's Indonesia launched a project called Dementia Friendly Jakarta with the governor's support. In 2012, there were nearly 21 million older people, and the projected number of patients suffering from Alzheimer's is expected to reach about 5,18,000 by 2024, supplementing the growth of the Indonesia Alzheimer's disease therapeutics & diagnostics market.

COMPETITIVE INSIGHTS

Prominent companies operating in the market include: Sun Pharmaceuticals Industries Ltd, GE Healthcare, Lupin Limited, Novartis AG, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 16805

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING GERIATRIC POPULATION
    • 3.2.2. RISING PERVASIVENESS OF ALZHEIMER'S DISEASE
    • 3.2.3. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
    • 3.2.4. INCREASING PIPELINE DRUGS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. FAILURE OF THE LATE-STAGE DRUGS
    • 3.3.2. STRINGENT GOVERNMENT REGULATIONS
    • 3.3.3. LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4. KEY ANALYTICS

  • 4.1. TIMELINE OF ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 4.2. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 4.3. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 4.4. KEY MARKET TRENDS
  • 4.5. PORTER'S FIVE FORCES ANALYSIS
    • 4.5.1. BUYERS POWER
    • 4.5.2. SUPPLIERS POWER
    • 4.5.3. SUBSTITUTION
    • 4.5.4. NEW ENTRANTS
    • 4.5.5. INDUSTRY RIVALRY
  • 4.6. KEY BUYING CRITERIA
  • 4.7. SUPPLY CHAIN ANALYSIS
  • 4.8. OPPORTUNITY MATRIX
  • 4.9. VENDOR LANDSCAPE

5. MARKET BY THERAPEUTICS & DIAGNOSTICS

  • 5.1. THERAPEUTICS
    • 5.1.1. DRUGS
      • 5.1.1.1. MARKETED DRUGS
      • 5.1.1.2. PIPELINE DRUGS
    • 5.1.2. DISEASE STAGE
      • 5.1.2.1. LATE-STAGE: SEVERE AD
      • 5.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 5.1.2.3. PRODROMAL STAGE
    • 5.1.3. GENERIC & BRANDED
      • 5.1.3.1. BRANDED
      • 5.1.3.2. GENERIC
  • 5.2. DIAGNOSTICS
    • 5.2.1. LUMBAR PUNCTURE TEST
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY
    • 5.2.3. ELECTROENCEPHALOGRAPHY
    • 5.2.4. MAGNETIC RESONANCE IMAGING
    • 5.2.5. COMPUTED TOMOGRAPHY
    • 5.2.6. BLOOD TEST
    • 5.2.7. OTHER DIAGNOSTICS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. ASIA-PACIFIC
    • 6.1.1. MARKET SIZE & ESTIMATES
    • 6.1.2. KEY GROWTH ENABLERS
    • 6.1.3. KEY CHALLENGES
    • 6.1.4. KEY PLAYERS
    • 6.1.5. COUNTRY ANALYSIS
      • 6.1.5.1. CHINA
      • 6.1.5.2. JAPAN
      • 6.1.5.3. INDIA
      • 6.1.5.4. SOUTH KOREA
      • 6.1.5.5. INDONESIA
      • 6.1.5.6. THAILAND
      • 6.1.5.7. VIETNAM
      • 6.1.5.8. AUSTRALIA & NEW ZEALAND
      • 6.1.5.9. REST OF ASIA-PACIFIC

7. COMPETITIVE LANDSCAPE

  • 7.1. KEY STRATEGIC DEVELOPMENTS
    • 7.1.1. MERGERS & ACQUISITIONS
    • 7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 7.1.3. PARTNERSHIPS & AGREEMENTS
    • 7.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
  • 7.2. COMPANY PROFILES
    • 7.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • 7.2.2. AMARANTUS BIOSCIENCE HOLDINGS INC
    • 7.2.3. BAXTER INTERNATIONAL INC
    • 7.2.4. BIOGEN INC
    • 7.2.5. COGNOPTIX INC
    • 7.2.6. EISAI CO LTD
    • 7.2.7. ELI LILLY & COMPANY
    • 7.2.8. F HOFFMANN-LA ROCHE
    • 7.2.9. GE HEALTHCARE
    • 7.2.10. JOHNSON & JOHNSON
    • 7.2.11. LUPIN LIMITED
    • 7.2.12. MERCK & CO INC
    • 7.2.13. NOVARTIS AG
    • 7.2.14. PFIZER INC
    • 7.2.15. SIEMENS HEALTHINEERS AG
    • 7.2.16. SUN PHARMACEUTICALS INDUSTRIES LTD
    • 7.2.17. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.2.18. ZYDUS CADILA

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS
  • TABLE 2: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 3: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 4: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 5: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 6: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 7: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 8: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 9: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 10: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 11: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 12: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 13: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 14: LEADING PLAYERS OPERATING IN ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • TABLE 15: LIST OF MERGERS & ACQUISITIONS
  • TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER'S DISEASE
  • FIGURE 2: KEY MARKET TRENDS
  • FIGURE 3: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 4: KEY BUYING CRITERIA
  • FIGURE 5: SUPPLY CHAIN ANALYSIS
  • FIGURE 6: OPPORTUNITY MATRIX
  • FIGURE 7: VENDOR LANDSCAPE
  • FIGURE 8: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021
  • FIGURE 9: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 10: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021
  • FIGURE 11: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)
  • FIGURE 12: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)
  • FIGURE 13: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021
  • FIGURE 14: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)
  • FIGURE 15: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)
  • FIGURE 16: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)
  • FIGURE 17: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021
  • FIGURE 18: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)
  • FIGURE 19: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)
  • FIGURE 20: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 21: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021
  • FIGURE 22: ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)
  • FIGURE 23: ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 24: ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 25: ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)
  • FIGURE 26: ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 27: ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)
  • FIGURE 28: ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 29: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 30: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 31: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 32: INDIA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 34: INDONESIA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 35: THAILAND ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 36: VIETNAM ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 37: AUSTRALIA & NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 38: REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)